Stable, synthetic analogs of diadenosine tetraphosphate inhibit rat and human P2X3 receptors and inflammatory pain

Viacheslav Viatchenko-Karpinski, PhD1,2, Natalia Novosolova, PhD3, Yevheniia Ishchenko, MSc3, M Ameruddin Azhar, PhD4,5, Michael Wright, PhD5,6, Vera Tsintsadze, PhD7,8, Ahmed Kamal, PhD4, Nail Burnashev, PhD, DrSc7,8, Andrew D Miller, PhD6,9, Nana Voitenko, PhD, DrSc1,2, Rashid Giniatullin, MD, PhD3,10 and Natalia Lozovaya, PhD, DrSc7,8,11

Abstract

Background: A growing body of evidence suggests that ATP-gated P2X3 receptors (P2X3Rs) are implicated in chronic pain. We address the possibility that stable, synthetic analogs of diadenosine tetraphosphate (Ap4A) might induce antinociceptive effects by inhibiting P2X3Rs in peripheral sensory neurons.

Results: The effects of two stable, synthetic Ap4A analogs (AppNHppA and AppCH2ppA) are studied firstly in vitro on HEK293 cells expressing recombinant rat P2XRs (P2X2Rs, P2X3Rs, P2X4Rs, and P2X7Rs) and then using native rat brain cells (cultured trigeminal, nodose, or dorsal root ganglion neurons). Thereafter, the action of these stable, synthetic Ap4A analogs on inflammatory pain and thermal hyperalgesia is studied through the measurement of antinociceptive effects in formalin and Hargreaves plantar tests in rats in vivo. In vitro inhibition of rat P2X3Rs (not P2X2Rs, P2X4Rs nor P2X7Rs) is shown to take place mediated by high-affinity desensitization (at low concentrations; IC50 values 100–250 nM) giving way to only weak partial agonism at much higher concentrations (EC50 values ≥ 10 μM). Similar inhibitory activity is observed with human recombinant P2X3Rs. The inhibitory effects of AppNHppA on nodose, dorsal root, and trigeminal neuron whole cell currents suggest that stable, synthetic Ap4A analogs inhibit homomeric P2X3Rs in preference to heteromeric P2X2/3Rs. Both Ap4A analogs mediate clear inhibition of pain responses in both in vivo inflammation models.

Conclusions: Stable, synthetic Ap4A analogs (AppNHppA and AppCH2ppA) being weak partial agonist provoke potent high-affinity desensitization-mediated inhibition of homomeric P2X3Rs at low concentrations. Therefore, both analogs demonstrate clear potential as potent analgesic agents for use in the management of chronic pain associated with heightened P2X3R activation.

Keywords

P2X3 receptors, high-affinity desensitization, stable synthetic diadenosine tetraphosphate analogs, inflammatory pain, dorsal root ganglion

Date received: 8 November 2015; accepted: 8 December 2015
Introduction

Chronic pain syndrome occurs and persists in a heterogeneous group of etiologically different diseases. It is classified into nociceptive, inflammatory, and neuropathic pain; however, a comorbid mix of both components frequently occurs in postsurgical, osteoarthritic, cancer-related, and back pain. Nociceptive inflammatory pain, in particular, is caused by tissue damage and subsequent release of inflammatory mediators, which leads to the sensitization of peripheral nociceptors.1,2 Despite intensive exploration, few treatments of chronic nociceptive pain are known to be effective. ATP-gated P2X3 (P2X3R) and heteromeric P2X2/3 receptors expressed in nociceptive neurons are involved in various chronic pain states.3–5 P2X3Rs substantially contribute toward the transmission of pain signals6–13 and, therefore, appear to be an appropriate therapeutic target for the treatment of chronic nociceptive pain. The key role of P2X3Rs in the transmission of nociceptive signals has been confirmed by the knockout of P2X2R and P2X3R8,14,15 genes and by means of siRNA16 or antisense oligonucleotide-mediated gene knockdown.17,18

Critically, P2X3R antagonists have analgesic effects in nociceptive and neuropathic pain models.11,12,19–21 Indeed several novel nonnucleotide antagonists have been shown to inhibit the activities of P2X3Rs in nociceptive or neuropathic pain models.22–28 However, despite significant advances in the exploration of P2X3R pharmacology, potent P2X3R-selective antagonists/inhibitors are in relatively short supply. To date, only one major P2X3R-selective antagonist (AF219) has been evaluated in clinic for the relief of pain.23 In seeking alternatives, the unusual gating of homeric P2X3Rs opens up new possibilities for inhibition. Of particular relevance, P2X3Rs exhibit fast desensitization (in the millisecond range) with a very slow recovery (several minutes).29–31 Indeed, some agonists such as ATP readily induce use-dependent high-affinity desensitization (HAD) of P2X3Rs.32,33 Accordingly, a ligand to be discovered that was able to induce HAD while functioning only as a weak agonist, then such a ligand could be a powerful pharmacological tool for P2X3R inhibition and a potentially powerful pharmaceutical tool for the inhibition of pain effects. It is in this context that we have been examining the effects of stable, synthetic diadenosine polyphosphate analogs on pain, specifically with reference to P2X3Rs.

Methods

ApₙA analog syntheses

AppNHppA and AppCH₂ppA were prepared using LysU-mediated synthetic–biosynthetic (chemo-enzymatic) procedures as described previously42,43 with rigorous purification by high-performance liquid chromatography.44,45

Cell cultures and transfection

Rat trigeminal, nodose, or dorsal root ganglion (TG, NG, and DRG, respectively) neurons in culture were prepared using poly-L-lysine (0.2 mg/ml)-coated Petri dishes and cultured for one to two days under an atmosphere containing 5% CO₂. Cells were used within two days of plating when they lacked processes. HEK293T cells were prepared as reported previously32,48 and transfected with rat or human full-length P2X3 cDNA subcloned into pIRES2-EGFP (Clontech, Mountain View, CA, USA).

Electrophysiological recordings

TG, NG, DRG, or HEK cells were recorded in the whole-cell configuration while being continuously depolarized. ApₙAs are released in a Ca²⁺-dependent manner34 and their potential role as neurotransmitters has been proposed.35–37 ApₙAs are known as agonists of some P2XRs and P2YRs.38–40 Ap₄A and Ap₅A have also been shown to induce potent desensitization of recombinant P2X3Rs.41 Unfortunately, the pharmaceutical and therapeutic potential of ApₙAs is limited by the fact that ApₙAs undergo specific enzymatic cleavage and also nonspecific hydrolytic breakdown in vivo. Fortunately, this in vivo lability issue can be overcome by using synthetic methods to replace one or more of the oxo-bridges in a polyphosphate chain with either aza- or carba-bridges. Here, we report on the effects of using two stable, synthetic Ap₄A analogs—AppCH₂ppA (diadenosine 5′,5′′-P₁,P₄-(β,γ-methylene)tetraphosphate) and AppNHppA (diadenosine 5′,5′′-P₁,P₄-(β,γ-imido)tetraphosphate)—in a range of in vitro studies designed to understand the mechanism of action and efficacy of these Ap₄A analogs for the control and management of nociceptive pain responses. Here we show that both induce potent, use-dependent HAD of P2X3Rs (strong antinociceptive activity), while in contrast both are found to be weak, partial P2X3R agonists (weak pronociceptive activity). In addition, we show that both analogs are able to exert potent antinociceptive activities in in vivo animal models of inflammatory pain. Therefore, both could indeed be very powerful pharmaceutical agents for P2X3R inhibition and for the inhibition of nociceptive pain effects.
superfused (at 2 ml/min) with control solution containing (in mM): 152 NaCl, 5 KCl, 1 MgCl₂, 2 CaCl₂, 10 glucose, and 10 HEPES; pH was adjusted to 7.4 with NaOH and osmolarity was adjusted to 320 mOsM with glucose. Patch pipettes had a resistance of 3 to 4 MΩ when filled with an intracellular equivalent solution containing (in mM): 130 CsCl, 0.5 CaCl₂, 5 MgCl₂, 5 K₂ATP, 0.5 NaGTP, 10 HEPES, and 5 EGTA; pH was adjusted to 7.2 with CsOH. Responses to selective P2X3R agonist α,β-methylene-ATP (α,β-meATP; resistant to ectoATPase hydrolysis, Sigma-Aldrich) were measured using an EPC-9 amplifier operated by HEKA Patch Master software (HEKA Electronik, Germany). Cells were voltage-clamped at −70 mV. In most cells, series resistance was compensated by 80%. To determine EC₅₀ values, dose-response curves were constructed for α,β-meATP by administering different agonist doses same cells and fitting data to a logistic equation (Origin 8.0, Microcal, Northampton, MA).

Drug delivery

Agonists and antagonists were applied (usually for 2 s) via a rapid superfusion system (Rapid Solution Changer RSC-200; BioLogic Science Instruments, Grenoble, France) placed 100 to 150 µm near the cell. The time for the solution exchange across the cell was approximately 30 ms, as judged with liquid junction potential measurements. All chemicals, including enzymes for cell culture, were from Sigma-Aldrich (St. Louis, MO). Culture media were obtained from Invitrogen (Milan, Italy).

Measurement of nociceptive behavior in formalin test

All animal experiments were carried out in accordance with the “Guide for the Care and Use of Laboratory Animals” as adopted by the Bogomoletz Institute of Physiology Clinic of Animal Care and Use. The formalin test experiments were performed on 21-day-old male Wistar rats, weighing 40 ± 5 g according to the method described previously. Briefly, animal was acclimated to an acrylic observation chamber for at least 1 h before the injection of formalin (50 µl of 0.5% solution in 0.9% saline) into the dorsal surface of the right hindpaw. Immediately after the injection, each animal was returned to the observation chamber and its behavioral characteristics were recorded for 45 min. We noticed consistently observed type of response: spontaneous jerking of the injected paw. The number of jerks was measured for each 1-min block, using self-developed computer software.

Measurement of hindpaw thermal hyperalgesia

To induce chronic inflammatory hyperalgesia, rats were injected with complete Freund’s adjuvant (CFA, 100 µl of 50% solution) into the plantar surface of the right hindpaw 24 h prior to testing. Control animals were injected with 100 µl of pure saline. Injections of AppCH₂ppA and AppNHppA (100 nM–100 µM) in 100 µl of 0.9% saline were made just before the beginning of the plantar test.

For intrathecal injection, a polyethylene-10 catheter was inserted into the rat’s subarachnoid space through a small incision at the cisterna magna, and the tip of the catheter was implanted at the L4 spinal segmental level. Animals were allowed to recover for at least four days before behavior tests. AppCH₂ppA or vehicle (saline) was injected intrathecally (10 µl) and flushed with 10 µl of saline.

The Hargreaves technique was used for thermal hyperalgesia studies (using the Ugo Basile Model 7370 Plantar Test). Paw withdrawal responses to noxious heat stimuli were measured in rats as described. To measure response to noxious heat stimuli, each animal was placed in a Plexiglas chamber on a glass plate located above a light box. Radiant heat was applied by focused infrared (IR) beam to the middle of the plantar surface of rat hindpaw. When the animal lifted its foot, the IR beam was turned off. The time interval between the start of the IR beam and the foot lift was defined as the paw withdrawal latency. Each trial was repeated 13 times at 20-min intervals for each paw. A cut-off time of 30 s was used to prevent paw tissue damage.

Data analysis

The peak amplitudes of the responses were measured using HEKA Patch Master software. For each agonist, dose-response plots were constructed by normalizing data with respect to the maximum response. All data are presented as mean ± SEM (n = the number of cells) with statistical significance assessed by paired t-test (for parametric data) or Mann-Whitney rank-sum test (for nonparametric data). Best fits of data with a sigmoid function were compared with respective control fits using Origin 8.0 software. A value of p < 0.05 was accepted as indicative of statistically significant difference.

Results

Inhibitory effects and weak agonist effects of stable Ap₄A analogs acting on recombinant rat homomeric P2X3 receptors

Previous publications have demonstrated that several diadenosine polyphosphates (such as Ap₄A and Ap₃A) might be full agonists of rat P2X3R. In our experiments using HEK293 cells expressing rat homomeric P2X3R, the stable, synthetic analog AppNHppA was
found not to induce membrane currents at concentrations of 0.1 or 1 \( \mu \)M. However, small and slowly desensitizing currents were generated by 10 or 100 \( \mu \)M AppNHppA (Figure 1(a)). To test whether AppNHppA is a full or partial agonist of P2X3Rs, we compared AppNHppA-induced responses with those induced by the full agonist of P2X3 receptors \( \alpha_2\beta\)-meATP (10 \( \mu \)M, left) and saturating (1 mM, right) concentration of AppNHppA in the same cell. Note significantly smaller amplitude of the latter. (c) Bar graphs showing mean \pm SEM amplitude of currents induced by \( \alpha_2\beta\)-meATP at 10 \( \mu \)M and AppNHppA at different concentrations (10 \( \mu \)M–1 mM), \( n = 7 \). Inset: molecular structure of AppNHppA. Here and below * \( p < 0.05 \), ** \( p < 0.001 \), and *** \( p < 0.0001 \).

Figure 1. Partial agonist activity of AppNHppA at rat homomeric P2X3 receptors. (a): Example of responses induced by different concentrations of AppNHppA (1 \( \mu \)M–100 \( \mu \)M) applied for 2 s to HEK cells expressing rat P2X3 receptors. (b) Comparison of currents induced by the full agonist of P2X3 receptors \( \alpha_2\beta\)-meATP (10 \( \mu \)M, left) and saturating (1 mM, right) concentration of AppNHppA in the same cell. Note significantly smaller amplitude of the latter. (c) Bar graphs showing mean \pm SEM amplitude of currents induced by \( \alpha_2\beta\)-meATP at 10 \( \mu \)M and AppNHppA at different concentrations (10 \( \mu \)M–1 mM), \( n = 7 \). Inset: molecular structure of AppNHppA. Here and below * \( p < 0.05 \), ** \( p < 0.001 \), and *** \( p < 0.0001 \).

At subthreshold concentrations, certain P2X3R agonists can inhibit receptor function via the mechanism of HAD. Therefore, the inhibitory potency of AppNHppA against P2X3R was evaluated for the potential existence of this HAD effect. To examine for this, repetitive 2-s-long activations of P2X3R (2-min interpulse interval) were induced using \( \alpha_2\beta\)-meATP (10 \( \mu \)M) as the full agonist (later on test-pulse) before and after AppNHppA administration (for protocol, see Figure 2 top). When 10 nM of AppNHppA was applied after a control test response to \( \alpha_2\beta\)-meATP, the amplitude of the following response was almost unchanged (Figure 2(a)). However, when 3 \( \mu \)M of AppNHppA was administered, a complete inhibition of test responses was induced indicative of the HAD effect (Figure 2(b)). Notably, AppNHppA administered at a concentration below the activation threshold (100 nM; see Figure 2(d)) induced a strong HAD effect on test
responses, reducing them by $38.2 \pm 8.5\%$ ($n = 7, p = 0.002$). The time course for these HAD inhibitory effects of AppNHppA is shown in Figure 2(c), and the concentration dependence measured at condition approaching saturation (6 min after drug application) suggests an IC$_{50}$ value of $0.20 \pm 0.04\mu M$ ($n = 3–6$) (Figure 2(d)). Importantly, the HAD inhibitory curve for AppNHppA did not overlap with the partial agonist P2X3R-activation curve, since the partial agonist effects of AppNHppA on P2X3Rs appeared to require much higher concentrations (EC$_{50} = 41.6 \pm 1.3\mu M$; $n_{14} = 1.58 \pm 0.05; n = 8$; Figure 2(d)). Thus, AppNHppA exhibits a unique profile of activity with a high EC$_{50}$ of $41\mu M$ and low IC$_{50}$ of $200\mathrm{nM}$. Should we use the EC$_{50}$/IC$_{50}$ ratio as an indication of activation/inhibition or as an safety/efficiency, then the ratio for AppNHppA is 205, which is ~20 times higher than corresponding index values for ATP (15.13) and endogenous Ap$_{4}$A (11.48) (relevant EC$_{50}$ and IC$_{50}$ values for ATP and Ap$_{4}$A were taken from literature$^{41}$). For comparison, the HAD inhibitory effects mediated by stable, synthetic Ap$_{4}$A analog AppCH$_{2}$ppA were found similar to those induced by AppNHppA (IC$_{50} = 0.55 \pm 0.2\mu M$, $n = 4–7$; Figure 3(a) and (d)), although the partial agonist effect was apparently stronger (EC$_{50} = 9.30 \pm 1.7\mu M$; $n_{14} = 2.27 \pm 0.56; n = 5$; Figure 3(d)).

Figure 2. Activation and inhibition of rat P2X3 receptors by AppNHppA. Top: Experimental protocol. Test pulses of $10\mu M$ of $\alpha,\beta$-meATP were delivered every 2 min. After two control pulses, AppNHppA at different concentrations was applied for 6 min. Example traces of P2X3R-mediated currents in control and after 2 min application of 10 nM (a) and 3 $\mu M$ (b) of AppNHppA (corresponding to the part of the experimental protocol outlined by a dotted box). (c) The time course of the current inhibition by AppNHppA at different (1 nM–3 $\mu M$) concentrations ($n = 4–6$). Current amplitudes are normalized to control. (d) Dose-response curves for the activation and inhibition of P2X3-mediated currents by AppNHppA.
To understand the nature of the inhibitory action of Ap₄A analogs, we applied AppCH₂ppA to cells stimulated with test pulses either every 2 min or 30 s. Interestingly, with an increased frequency of agonist applications (30 s intervals; Figure 3(b) and (c)), when the fraction of P2X3R in desensitized state was enhanced, the inhibitory activity of AppCH₂ppA was significantly increased (depression by 81.3% vs 61.3% at low rate, \(p = 0.014, n = 7\)), suggesting that a depressant effect on P2X3R is use-dependent, via the HAD mechanism.

In contrast, in separate experiments with recombinant P2X2Rs, P2X4Rs, or P2X7Rs expressed in HEK 293 cells, the application of AppNHppA did not produce any HAD or partial agonism effects on any of these receptor-mediated currents (Figure 4). Altogether these data indicate that both stable, synthetic Ap₄A analogs appear to induce selective inhibition of recombinant P2X3Rs by use-dependent HAD, and exercise partial agonism at best at substantially higher, nonoverlapping concentrations. To test for the possible involvement of metabotropic G-protein coupled P2Y receptors in the observed phenomena of P2X3R inhibition by Ap₄A analogs, we performed experiments using a nonhydrolyzable analog of GDP and competitive inhibitor of G-proteins, GDP-β-S, (500 μM) introduced into cells. Under these conditions, the inhibitory action of AppNHppA remained unchanged (Figure 5). These results clearly rule out the involvement of P2YRs.

Next the effects of AppNHppA on native P2X3Rs in TG, DRG, and NG neurons were investigated. Decay kinetics of ATP response in situ strongly depends on differential contributions from P2X2R and P2X3R subunits.46,54 Fast desensitizing (fast) responses (within 1 s from agonist application) correlate with contributions of P2X2/3Rs.12,15 Notably, only homomeric P2X3Rs and heteromeric P2X2/3Rs are activated by \(10 \mu M \alpha,\beta\)-meATP. Following administration of test pulses of \(\alpha,\beta\)-meATP, responses induced in TG neurons were found to be fast (56% of the cells) and mixed (composite of fast and slow desensitizing responses) (44% of the cells), but without slow-type responses (0% of the cells, \(n = 18\) cells) (Figure 6(a)). In DRG neurons (\(n = 8\)), responses induced were 50% fast, 50% mixed, and 0% slow, whereas in NG neurons (\(n = 11\)), responses induced were 22% fast, 0% mixed, and 78% slow (Figure 6(a)). These data indicate that TG neurons and DRG cells predominantly express homomeric P2X3Rs, while NG neurons express heteromeric P2X2/3Rs subunits. Importantly, administration of AppNHppA (1 μM) selectively inhibited fast responses (Figure 6(b) and (c)), with little effect on
mixed or slow responses (Figure 6(d)). Indeed, inhibition of peak currents was observed to be 80.3 ± 4.4% (n = 9, P = 0.0004) in TG neurons, 79.2 ± 5.6% (n = 6, p = 0.02) in DRG neurons and only 16.8 ± 11.8% (n = 9, p > 0.05) in NG neurons (Figure 6(e) to (g)). Furthermore, sustained residual components were less inhibited (15 ± 6%, 18 ± 6%, and 2 ± 4% for TG, DRG, and NG neurons, respectively; Figure 6(e) to (g)). Accordingly, these data interlock to support the view that inhibition of cellular responses by AppNHppA is essentially mediated through homomeric P2X3Rs alone and not heteromeric P2X2/3Rs. These data are also consistent with the fact that AppNHppA is also unable to elicit any responses from recombinant P2X2Rs (see earlier). Furthermore, these data obtained with native neurons are completely consistent with our results from studies with recombinant homomeric P2X3Rs (Figures 2 and 3).

Figure 4. AppNHppA does not inhibit homomeric P2X2, P2X4, and P2X7 receptors. (a) Representative traces of responses induced by 10 μM of ATP applied for 2 s every 2 min to HEK293 cells expressing rat P2X2, P2X4, and P2X7 receptors in control, in the presence, and after wash out of AppNHppA (1 μM). (b) Bar graphs of the effects of AppNHppA on the amplitude of P2X2, P2X4, and P2X7 receptor-mediated currents.

Figure 5. Effect of AppNHppA on P2X3 is not altered in the presence of G-protein inhibitor. Example traces of P2X3-mediated currents in control and after 6 min application of 1 μM AppNHppA with GTP (500 μM, (a)) or GDP-β-S (500 μM, (b)) in the intracellular solution. (c) Bar graph showing the inhibitory action of AppNHppA on P2X3 receptors with GTP and GDP-β-S (23.41 ± 2.01%, n = 4, p < 0.05 for GTP and 23.93 ± 5.24, n = 5, p = 0.007 for GDP-β-S).
Inhibition of human P2X3 receptors by Ap4A analogs

Next we tested the inhibitory action of AppNHppA and AppCH2ppA in recombinant human P2X3Rs (hP2X3Rs) expressed in HEK293 cells. The inhibitory potency of AppNHppA on hP2X3Rs was found as strong as with rat P2X3Rs (Figure 7). Notably, even 10 nM AppNHppA significantly reduced currents activated by the P2X3R agonist α,β-meATP to 80 ± 5% \((n=4, \ p < 0.01 \text{ by paired } t\text{-test})\) of control values, whereas 100 nM AppNHppA inhibited test responses to 48 ± 8% of control \((n=6, \ p < 0.01)\); and 1 μM AppNHppA inhibited test currents to 12 ± 4% of control \((n=3, \ p < 0.01)\) (Figure 7(b) and (c)). Interestingly,

![Figure 6](image)

**Figure 6.** Selective inhibition of P2X3 subunit containing receptors by AppNHppA in rat sensory neurons. (a) The relative proportion of cells with fast, mixed and slow current types elicited by α β-meATP in trigeminal (TG), dorsal root (DRG), or nodose (NG) neurons. Typical examples of fast, mixed, and slow currents are shown in panels (b) to (d), respectively. Examples showing inhibitory action of AppNHppA (1 μM, 6 min application) on responses evoked by 10 μM α,β-meATP in TG (b), DRG (c), and NG (d) ganglia neurons, respectively. Note preferential inhibition of fast currents. Bar graphs showing the inhibitory action of AppNHppA on fast (peak) and slow (residual, at the end of α,β-meATP application) currents in different ganglia in TG (e), DRG (f), or NG (g) neurons.
the activation of the currents by AppNHppA (partial agonist activity) was observed only in concentrations exceeding 10 μM similar to results obtained with rat P2X3Rs (Figure 2(d)), in contrast to inhibitory activities that were observed at concentrations 10^3 lower, once again demonstrating the very low agonist activity of this compound. Likewise, the inhibitory effect of AppCH2ppA on hP2X3Rs at the subthreshold concentration of 100 nM (56 ± 7%, n = 6, p < 0.01) (Figure 7(d) and (e)) was also as strong as on rat P2X3Rs (Figure 3(d)). Notably, responses recovered from inhibition after washout of the both inhibitory agents. No
depression was observed in control experiments with the same regular applications of α,β-meATP but without adding Ap4A analogs (Figure 7).

**Antinociceptive effects of stable, synthetic Ap4A analogs in vivo**

The effects of AppNHppA and AppCH2ppA were examined on the behavioral reactions of rats in inflammatory pain models. The injection of diluted formalin into an animal’s hindpaw produces a biphasic nociceptive response consisting of immediate (acute phase) and tonic (inflammatory phase) components. The first (acute) phase of a formalin response (i.e., 0–5 min after injection) involves a direct effect of formalin on the nociceptive receptors, while changes in animal behavior during the tonic (chronic) phase (i.e., 7–45 min after injection) are caused by hyperalgesia that develops due to the sensitization of nociceptive and spinal neurons via mechanisms that are triggered by repetitive stimulation during the acute phase. Coinjection of AppNHppA or AppCH2ppA and formalin into the inflamed paw of rats reduced potently the number of nocifensive events triggered by formalin. IC50 values were calculated for acute and chronic phases based on the locally administered concentrations of AppNHppA or AppCH2ppA and assuming negligible dilution in tissue postadministration prior to effects on receptors. Accordingly, the IC50 value for AppCH2ppA in the tonic phase was 0.29 ± 0.05 μM, kH = 1.15 ± 0.17, whilst the IC50 value in the acute phase was 34.66 ± 13.21 μM; kH = 0.5 ± 0.14. In comparison, the IC50 value for AppNHppA in the tonic phase was 0.11 ± 0.02 μM, kH = 0.82 ± 0.1, while the IC50 value in the acute phase was > 100 μM (Figure 8). Specifically, post AppCH2ppA administration, nocifensive behavior was reduced 60 times more effectively in the tonic phase compared with the acute phase of the formalin assay (Figure 8). Calculations based upon the effective concentrations of AppCH2ppA and AppNHppA in the formalin model gave respective in vivo IC50 values of 0.72 nmol/kg (0.61 μg/kg) and 0.28 nmol/kg (0.23 μg/kg) of animal body weight. In control conditions, we observed no sign of nociceptive behavior after injection of Ap4A analogs alone in the absence of formalin challenge (Figure 9). Overall, these in vivo IC50 values for the tonic phase are in surprisingly good agreement with those IC50 values determined using Ap4A analogs acting on recombinant rat homomeric P2X3Rs (Figures 2 and 3).

Subsequently, we tested whether our stable, synthetic Ap4A analogs might possess analgesic properties in a model of chronic thermal hyperalgesia induced by the injection of CFA into rat hindpaws. In the Hargreaves plantar test (see Methods for details), an antinociceptive effect was observed during first 200 min following intraplantar injection of AppNHppA and AppCH2ppA into the inflamed hindpaw of rats with CFA-induced thermal hyperalgesia (Figure 10(a) and (b)). The effect became potent in 20 min after the injection of AppNHppA or AppCH2ppA and lasted next 180 min (a dashed box in Figure 10(a)). Importantly, intrathecal injection of AppCH2ppA (20 μM) induced significantly weaker and delayed antinociceptive effect on CFA-induced thermal hyperalgesia. The effects of intrathecal administration were observed only 120 min post AppCH2ppA injection and lasted only 60 min (a dashed box in Figure 10(c)) as compared to 180 min in the case of intraplantar injection. Furthermore, we observed that pain inhibition by intrathecal administration was only 22% compared to 58% inhibition following intraplantar administration (Figure 10(c) and (d)). It is worth noting that Ap4A analogs exhibited no obvious effects on thermal hyperalgesia in a sciatic nerve injury model and in a diabetic neuropathy model (data not shown).

**Discussion**

Two stable, synthetic Ap4A analogs (AppCH2ppA and AppNHppA) were studied and found to exhibit remarkably high levels of inhibitory activity on rat and human P2X3Rs that correlates with comparable high levels of antipain activity in the formalin pain model in vivo.

**Synthetic Ap4A analogs selectively inhibit P2X3Rs**

Importantly, P2X3Rs have been implicated in abnormal pain signaling in various states of chronic pain, including inflammatory and cancer-associated pain. Inflammatory mediators such as substance P and bradykinin potentiate currents through ATP-gated channels containing P2X3 subunits. Recently data suggest that nerve growth factor and protease-activated receptor 2 might trigger sensitization of pain through P2X3R activation. An increased expression of P2X3R has been described at peripheral nerves during painful neoplastic processes. Out of several subtypes of the ionotropic P2XRs, P2X3 subunit containing receptors are preferentially expressed in nociceptive sensory neurons and, therefore, might be therapeutic targets for the treatment of pain.

Several potential strategies might be evoked to counteract enhanced activities of P2X3Rs. Previous studies have shown that P2X3R antagonists or genetic deletion have analgesic effects on inflammatory and neuropathic pain models. P2X3Rs are known to exhibit fast onset desensitization in the presence of the agonist followed by an exceptionally slow recovery process. P2X3R homo-trimers are also known to be super-sensitive to HAD inhibition by very low concentrations of...
agonists such as ATP (nM levels). The process of HAD and slow re-sensitization were recently explained as a consequence of the quasi-trapping of receptors in desensitized states caused by fast agonist association but only slow dissociation. HAD is known to be almost absent in homomeric P2X2 and heteromeric P2X2/P2X3Rs. Consistent with this view, measurements using labeled ATP have demonstrated that ATP dissociation and receptor re-sensitization kinetics correlate closely. Since P2X3Rs are highly prone to desensitization, this mechanism would seem to present an ideal opportunity to diminish ATP-mediated chronic nociceptive pain, provided that potential analgesics were able to induce HAD without being potent agonists.

Figure 8. Effects of subcutaneous Ap4A analogs on pain responses induced by intraplantar (right hindpaw) formalin injection. Rats were subcutaneously injected with formalin solution alone (0.5%, 50 μl, control) or coinjected with the formalin solution and solutions with AppCH₂ppA (1 μM–100 μM, 100 μl) or AppNHppA (0.1 μM–100 μM, 100 μl). Age-matched control animals were injected with saline. (a) Time course of the effects of subcutaneous AppCH₂ppA (left) and AppNHppA (right) on the number of the spontaneous jerkings of the injected paw. (b) Bar graphs of the effects of AppCH₂ppA (b, c) and AppNHppA (d, e) on the integral number of spontaneous jerkings. Measurements were made during the acute phase (0–6 min) and tonic phase (7–45 min) of the formalin response. (f) Dose-response curves for AppCH₂ppA (left) and AppNHppA (right) during tonic and acute phases. For each concentration 6–7 rats were used.
Importantly, the antinociceptive effect of P2X3 receptor desensitization in vivo has been first shown in the seminal paper by Bland-Ward and Humphrey. The authors reported that pretreatment with a low dose of \( \alpha,\beta\)-meATP significantly inhibited nociceptive responses induced by \( \alpha,\beta\)-meATP itself; however, this pretreatment was not effective in formalin assay. Here, we demonstrate that stable, synthetic Ap4A analogs (AppCH2ppA and AppNHppA) are capable of high-affinity inhibition of rat or human P2X3Rs by stable, use-dependent HAD (but not other P2XRs known to be of significance to nociception) at concentrations that did not generate the macroscopic currents. Critically, these two Ap4A analogs (especially AppNHppA) are also found to be only weak agonists of P2X3Rs at higher, nonoverlapping concentrations. Furthermore, this inhibitory effect of our Ap4A analogs was almost absent in NG neurons, where \( \alpha,\beta\)-meATP generated mainly slow-type currents mediated by heteromeric P2X2/3Rs. In contrast, the inhibition was strong in neurons that preferentially express homomeric P2X3Rs that are particularly susceptible to desensitization. In toto, these results suggest that both synthetic, stable Ap4A analogs are able to mediate inhibition by stabilization of the desensitized receptor state. These distinctive properties interlock to support the fact that our stable, synthetic Ap4A analogs have characteristics highly appropriate for therapeutic applications directed at the management of chronic pain.

**Potential therapeutic applications of the Ap4A analogs**

Endogenous Ap4As are abundant in various tissues including CNS. However (as noted earlier), endogenous Ap4As are not only potent P2X3R agonists but they are also unstable, which limits their potential utility. However, unlike endogenous Ap4As, synthetic Ap4A analogs, prepared with chemical modifications, appear chemically and metabolically stable. Gratifyingly, the abilities of AppNHppA and AppCH2ppA to inhibit P2X3Rs appear to correlate well with analgesic activities. Indeed a recalculations of the effective concentrations of AppCH2ppA and AppNHppA in the formalin model gave respective in vivo IC50 values of 0.72 nmol/kg (0.61 \( \mu \)g/kg) and 0.28 nmol/kg (0.23 \( \mu \)g/kg) of animal body weight. Therefore, our compounds are effective antinociceptive at doses that compare well with reported P2X3R antagonists. Clearly, there is a good correlation between Ap4A analog P2X3R inhibition and analgesic activities observed in vivo. Accordingly, we would propose that use-dependent HAD of P2X3Rs is the main mechanism contributing to observed inflammatory pain relief mediated by our Ap4A analogs.

In support of this proposal, the tonic phase of the formalin test is known to be largely eliminated in P2X3R knock-out mice consistent with a primary role for P2X3R subunits in pain nociception in this pain model. In addition, the selectivity of Ap4A analogs for P2X3Rs over P2X2Rs and other P2XRs suggests that the inhibitory actions of our Ap4A analogs (especially AppNHppA) should block ATP-gated pain transmission preferentially in TG and DRG neurons as opposed to NG neurons. Future preclinical and clinical studies will help to assess whether Ap4A analogs are active as pain killers in TG neuron-related nociceptive pain such as migraine headaches (where the dominating involvement of P2X3Rs is caused by the migraine mediator calcitonin gene-related peptide (CGRP)). Similarly, preclinical and clinical studies will help to assess whether Ap4A analogs are active as pain killers in DRG cell-related nociceptive pain as well (such as abdominal visceral and somatic parietal pain, and bone cancer pain).

With respect to future preclinical and clinical evaluations, our experiments demonstrated that local
Peripheral intraplantar injections of \( \text{Ap}_4\text{A} \) analogs resulted in antinociceptive effects twofold greater than intrathecal administration (58% vs. 22%) following administration of \( \text{AppCH}_2\text{ppA} \). Furthermore the onset of antinociceptive action was much faster in the case of local injection too. These data are consistent with the primary involvement of peripheral P2X3Rs in antinociception rather than spinal P2X3Rs. Therefore, our \( \text{Ap}_4\text{A} \) analogs have a primary ability to prevent activation of nociceptive the development of pathological plasticity with sensitization in higher structures.

**Conclusion**

In summary, in this study we directly show that stable, synthetic analogs of \( \text{Ap}_4\text{A} \) are weak partial agonists of P2X3Rs that inhibit rat or human recombinant and native rat P2X3Rs at much lower concentrations by HAD that results in stabilization of the desensitized receptor state. Therefore, stable analogs of \( \text{Ap}_4\text{A} \) represent a new class of potent painkillers for chronic nociceptive pain in in vivo animal models, and potentially in humans. These antinociceptive effects (1) are selective; (2) exhibit use-dependent mechanisms of action; (3) act at the peripheral site where target P2X3Rs are located; and (4) are analogous to endogenous compounds. Thus, we suggest that stable, synthetic \( \text{Ap}_4\text{A} \) analogs could represent a new highly attractive class of analgesic for the management of chronic inflammatory pain states associated with high activities of nociceptive, ATP-gated receptor mechanisms.
Acknowledgments
The authors are grateful to ImuThes, London, UK, for original support to carry out some preliminary in vivo experiments.

Author contributions
All authors read and approved the final manuscript. VV-K, NN, and YI provided equal contribution to this study. ADM, NV, RG, and NL shared last authorship. NB, NL, NV, ADM, and RG: design of experiments; VV-K and NV: in vivo animal models and behavioral tests; NN, YI, and RG: experiments in recombinant and native P2X3Rs; ADM, MW, AA, and AK: synthesis of diadenosine polyphosphate analogs and data discussion; NB, NL, ADM, RG, MW, VT, and NV: joint contribution to manuscript writing.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors declare that they have no competing interests. ADM is a shareholder in GlobalAcorn Ltd. ADM, NB, NL, and RG are coapplicants on a patent application (PCT/GB2013/051377) relating to the use of stable, synthetic Ap4A analogs for the treatment of chronic pain. RG and YI are supported by the Finnish Academy (grant 277442).

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NASU Biotechnology, Functional Genomics and DFFD F47/066 Grants (N.V.). RG and YI are supported by the Finnish Academy (grant 277442).

References
1. Woolf CJ and Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765–1769.
2. Julius D and Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203–210.
3. Burnstock G. Purinergic P2 receptors as targets for novel analgesics. Pharmacol Ther 2006; 110: 433–454.
4. Nakatsuka T and Gu JG. P2X purinoceptors and sensory transmission. Pflugers Arch 2006; 452: 598–607.
5. North RA. P2X3 receptors and peripheral pain mechanisms. J Physiol 2004; 554: 301–308.
6. Burnstock G. P2X receptors in sensory neurones. Br J Anaesth 2000; 84: 476–488.
7. Chizh BA and Illes P. P2X receptors and nociception. Pharmacol Rev 2001; 53: 553–568.
8. Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000; 407: 1011–1015.
9. Jarvis MF, Burgard EC, McGarraughty S, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A 2002; 99: 17179–17184.
10. Kennedy C. P2X receptors: targets for novel analgesics? Neuroscientist 2005; 11: 345–356.
11. Kennedy C, Assis TS, Currie AJ, et al. Crossing the pain barrier: P2 receptors as targets for novel analgesics. J Physiol 2003; 553: 683–694.
12. North RA. The P2X3 subunit: a molecular target in pain therapeutics. Curr Opin Investig Drugs 2003; 4; 833–840.
13. Tsuda M, Hasegawa S and Inoue K. P2X receptors-mediated cytosolic phospholipase A2 activation in primary afferent sensory neurons contributes to neuropathic pain. J Neurochem 2007; 103: 1408–1416.
14. Cockayne DA, Dunn PM, Zhong Y, et al. P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol 2005; 567: 621–639.
15. Souslova V, Cesare P, Ding Y, et al. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 2000; 407: 1015–1017.
16. Dorn G, Patel S, Wotherspoon G, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004; 32: e49.
17. Barclay J, Patel S, Dorn G, et al. Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J Neurosci 2002; 22: 8139–8147.
18. Honore P, Kage K, Mikusa J, et al. Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain 2002; 99: 11–19.
19. Burnstock G. Purinergic receptors and pain. Curr Pharm Des 2009; 15: 1717–1735.
20. Burnstock G, Krugel U, Abbracchio MP, et al. Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol 2011; 95: 229–274.
21. Wirkrner K, Sperlagh B and Illes P. P2X3 receptor involvement in pain states. Mol Neurobiol 2007; 36: 165–183.
22. Burnstock G. Purinergic mechanisms and pain—an update. Eur J Pharmacol 2013; 716; 24–40.
23. Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal 2012; 8: 3–26.
24. Gever JR, Cockayne DA, Dillon MP, et al. Pharmacology of P2X channels. Pflugers Arch 2006; 452: 513–537.
25. Gever JR, Soto R, Henningsen RA, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol 2010; 160: 1387–1398.
26. Gonzalez-Rodriguez S, Pevida M, Roques BP, et al. Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors. Neurosci Lett 2009; 465: 285–289.
27. Grishin EV, Savchenko GA, Vassilevski AA, et al. Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain. Ann Neurol 2010; 67: 680–683.
28. North RA and Jarvis MF. P2X receptors as drug targets. Mol Pharmacol 2013; 83: 759–769.
29. Chen CC, Akopian AN, Sivilotti L, et al. A P2X purinoceptor expressed by a subset of sensory neurons. Nature 1995; 377: 428–431.
30. Cook SP and McCleskey EW. Desensitization, recovery and Ca(2+)-dependent modulation of ATP-gated P2X receptors in nociceptors. *Neuropharmacology* 1997; 36: 1303–1308.

31. Lewis C, Neidhart S, Holy C, et al. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. *Nature* 1995; 377: 432–435.

32. Sokolova E, Skorinkin A, Fabbretti E, et al. Agonist-dependence of recovery from desensitization of P2X(3) receptors provides a novel and sensitive approach for their rapid up or downregulation. *Br J Pharmacol* 2004; 141: 1048–1058.

33. Sokolova E, Skorinkin A, Moiseev I, et al. Experimental and modeling studies of desensitization of P2X3 receptors. *Mol Pharmacol* 2006; 70: 373–382.

34. Miras-Portugal MT, Gualix J and Pintor J. Presence of diadenosine polyphosphates in rat brain synaptic terminals. *Cell Calcium* 2000; 28: 239–248.

35. Pintor J, Diaz-Rey MA, Torres M, et al. Diadenosine polyphosphate receptors: interaction with other neurotransmitter systems. *Drug Dev Res* 2001; 52: 136–144.

36. Miras-Portugal MT, Gualix J and Pintor J. The neurotransmitter role of diadenosine polyphosphates. *FEBS Lett* 1998; 436: 78–82.

37. Pintor J, Diaz-Hernandez M, Gualix J, et al. Diadenosine polyphosphate receptors: from rat and guinea-pig brain to human nervous system. *Pharmacol Ther* 2000; 87: 103–115.

38. Coddou C, Yan Z, Obsil T, et al. Activation and regulation of purinergic P2X receptor channels. *Pharmacol Rev* 2011; 63: 641–683.

39. Jacobson K and Linden J. Pharmacology of purine and pyrimidine receptors. San Diego, CA: Academic Press, 2011.

40. Wildman SS, Brown SG, King BF, et al. Selectivity of diadenosine polyphosphates for rat P2X receptor subunits. *Eur J Pharmacol* 1999; 367: 119–123.

41. McDonald HA, Chu KL, Bianchi BR, et al. Potent desensitization of human P2X3 receptors by diadenosine polyphosphates. *Eur J Pharmacol* 2002; 435: 135–142.

42. Melnik S, Wright M, Tanner JA, et al. Diadenosine polyphosphate analog controls postsynaptic excitation in CA3-CA1 synapses via a nitric oxide-dependent mechanism. *J Pharmacol Exp Ther* 2006; 318: 579–588.

43. Wright M, Azhar MA, Kamal A, et al. Syntheses of stable, synthetic diadenosine polyphosphate analogues using recombinant histidine-tagged lysyl tRNA synthetase (LysU). *Bioorg Med Chem Lett* 2014; 24: 2346–2352.

44. Azhar MA, Wright M, Kamal A, et al. Biotin-c10-AppCH2pA is an effective new chemical proteomics probe for diadenosine polyphosphate binding proteins. *Bioorg Med Chem Lett* 2014; 24: 2928–2933.

45. Wright M and Miller AD. Quantification of diadenosine polyphosphates in blood plasma using a tandem boronate affinity-ion exchange chromatography system. *Anal Biochem* 2013; 432: 103–105.

46. Sokolova E, Nistri A and Giniatullin R. Negative cross talk between anionic GABAA and cationic P2X ionotropic receptors of rat dorsal root ganglion neurons. *J Neurosci* 2001; 21: 4958–4968.

47. Simonetti M, Fabbro A, D’Arco M, et al. Comparison of P2X and TRPV1 receptors in ganglia or primary culture of trigeminal neurons and their modulation by NGF or serotonin. *Mol Pain* 2006; 2: 11.

48. Fabbretti E, Sokolova E, Masten L, et al. Identification of negative residues in the P2X3 ATP receptor ectodomain as structural determinants for desensitization and the Ca2+-sensing modulatory sites. *J Biol Chem* 2004; 279: 53109–53115.

49. Kamei J, Taki K, Ohsawa M, et al. Modulation of the formalin-induced nociceptive response by diabetes: possible involvement of intracellular calcium. *Brain Res* 2000; 862: 257–261.

50. Shibata M, Ohkubo T, Takahashi H, et al. Modified formalin test: characteristic biphasic pain response. *Pain* 1989; 38: 347–352.

51. Hargreaves K, Dubner R, Brown F, et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* 1988; 32: 77–88.

52. Tao CW, Chan ML and Lee TT. Adaptive fuzzy sliding mode controller for linear systems with mismatched time-varying uncertainties. *IEEE Trans Syst Man Cybern B Cybern* 2003; 33: 283–294.

53. Pratt EB, Brink TS, Bergson P, et al. Use-dependent inhibition of P2X3 receptors by nanomolar agonist. *J Neurosci* 2005; 25: 7359–7365.

54. Burgard EC, Niforatos W, van Biesen T, et al. P2X receptor-mediated ionic currents in dorsal root ganglion neurons. *J Neurophysiol* 1999; 82: 1590–1598.

55. Coderre TJ, Vaccarino AL and Melzack R. Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. *Brain Res* 1990; 535: 155–158.

56. Tjolsen A, Berge OG, Hunskaar S, et al. The formalin test: an evaluation of the method. *Pain* 1992; 51: 5–17.

57. O’Connor AB and Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. *Am J Med* 2009; 122: S22–S32.

58. Hartmann B, Ahmadi S, Heppenstall PA, et al. The selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice. *J Pharmacol* 2012; 688: 27–34.

59. Burnstock G. Targeting the visceral purinergic system for pain control. *Curr Opin Pharmacol* 2012; 12: 80–86.

60. Gilchrist LS, Cain DM, Harding-Rose C, et al. Reorganization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. *Brain Res* 2005; 1044: 197–205.

61. Hansen RR, Nasser A, Falk S, et al. Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice. *J Pharmacol* 2012; 688: 27–34.

62. Nagamine K, Ozaki N, Shinoda M, et al. Mechanical allodynia and thermal hyperalgesia induced by experimental squamous cell carcinoma of the lower gingiva in rats. *J Pain* 2006; 7: 659–670.

63. Wu JX, Xu MY, Miao XR, et al. Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain. *Eur J Pain* 2012; 16: 1378–1388.
64. Paukert M, Osteroth R, Geisler HS, et al. Inflammatory mediators potentiate ATP-gated channels through the P2X(3) subunit. *J Biol Chem* 2001; 276: 21077–21082.

65. D’Arco M, Giniatullin R, Simonetti M, et al. Neutralization of nerve growth factor induces plasticity of ATP-sensitive P2X3 receptors of nociceptive trigeminal ganglion neurons. *J Neurosci* 2007; 27: 8190–8201.

66. Giniatullin R, Nistri A and Fabbretti E. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. *Mol Neurobiol* 2008; 37: 83–90.

67. Liu J, Li JD, Lu J, et al. Contribution of nerve growth factor to upregulation of P2X(3) expression in DRG neurons of rats with femoral artery occlusion. *Am J Physiol Heart Circ Physiol* 2011; 301: H1070–H1079.

68. Wang S, Dai Y, Kobayashi K, et al. Potentiation of the P2X3 ATP receptor by PAR-2 in rat dorsal root ganglia neurons, through protein kinase-dependent mechanisms, contributes to inflammatory pain. *Eur J Neurosci* 2012; 36: 2293–2301.

69. Cook SP, Rodland KD and McCleskey EW. A memory for extracellular Ca2+ by speeding recovery of P2X receptors from desensitization. *J Neurosci* 1998; 18: 9238–9244.

70. North RA. Molecular physiology of P2X receptors. *Physiol Rev* 2002; 82: 1013–1067.

71. Bland-Ward PA and Humphrey PP. Acute nociception mediated by hindpaw P2X receptor activation in the rat. *Br J Pharmacol* 1997; 122: 365–371.

72. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes. Important modulators of purinergic signaling cascade. *Biochim Biophys Acta* 2008; 1783: 673–694.